|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis显示文摘 | Katrin M Sjoquist Bryan H Burmeister B Mark Smithers John R Zalcberg R John Simes Andrew Barbour Val Gebski | 2011 | Lancet Oncology2011，，7： | 4 |
| 2 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone. | Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill | 2015 | World Journal of Gastroenterology2015，21，17： | 3 |
| 3 | Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis显示文摘 | Val Gebski Bryan Burmeister B Mark Smithers Kerwyn Foo John Zalcberg John Simes | 2007 | Lancet Oncology2007，，3： | 1 |
| 4 | Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial显示文摘 | Bryan H Burmeister B Mark Smithers Val Gebski Lara Fitzgerald R John Simes Peter Devitt Stephen Ackland David C Gotley David Joseph Jeremy Millar John North Euan T Walpole James W Denham | 2005 | Lancet Oncology2005，，9： | 1 |
| 5 | Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis显示文摘 | Val Gebski Bryan Burmeister B Mark Smithers Kerwyn Foo John Zalcberg John Simes | 2007 | Lancet Oncology2007，，3： | 1 |
| 6 | Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis显示文摘 | Val Gebski Bryan Burmeister B Mark Smithers Kerwyn Foo John Zalcberg John Simes | 2007 | Lancet Oncology2007，，3： | 1 |
| 7 | Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis显示文摘 | Katrin M Sjoquist Bryan H Burmeister B Mark Smithers John R Zalcberg R John Simes Andrew Barbour Val Gebski | 2011 | Lancet Oncology2011，，7： | 1 |
| 8 | Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial显示文摘 | Bryan H Burmeister B Mark Smithers Val Gebski Lara Fitzgerald R John Simes Peter Devitt Stephen Ackland David C Gotley David Joseph Jeremy Millar John North Euan T Walpole James W Denham | 2005 | Lancet Oncology2005，，9： | 1 |
| 9 | Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial显示文摘 | Bryan H Burmeister B Mark Smithers Val Gebski Lara Fitzgerald R John Simes Peter Devitt Stephen Ackland David C Gotley David Joseph Jeremy Millar John North Euan T Walpole James W Denham | 2005 | Lancet Oncology2005，，： | 1 |
| 10 | Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis显示文摘 | Katrin M Sjoquist Bryan H Burmeister B Mark Smithers John R Zalcberg R John Simes Andrew Barbour Val Gebski | 2011 | Lancet Oncology2011，，7： | 1 |
| 11 | Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis显示文摘 | Val Gebski Bryan Burmeister B Mark Smithers Kerwyn Foo John Zalcberg John Simes | 2007 | Lancet Oncology2007，，3： | 1 |
| 12 | Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial显示文摘 | Bryan H Burmeister B Mark Smithers Val Gebski Lara Fitzgerald R John Simes Peter Devitt Stephen Ackland David C Gotley David Joseph Jeremy Millar John North Euan T Walpole James W Denham | 2005 | Lancet Oncology2005，，9： | 1 |
| 13 | Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis显示文摘 | Katrin M Sjoquist Bryan H Burmeister B Mark Smithers John R Zalcberg R John Simes Andrew Barbour Val Gebski | 2011 | Lancet Oncology2011，，7： | 1 |
| 14 | Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis显示文摘 | Val Gebski Bryan Burmeister B Mark Smithers Kerwyn Foo John Zalcberg John Simes | 2007 | Lancet Oncology2007，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员